Adam Boxer Selected Research

Neurodegenerative Diseases (Neurodegenerative Disease)

1/2018	Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY).
3/2016	Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD.
1/2016	Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.
1/2013	PET imaging of neuropathology in tauopathies: progressive supranuclear palsy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Adam Boxer Research Topics

Disease

17	Alzheimer Disease (Alzheimer's Disease) 04/2024 - 11/2007
10	Frontotemporal Dementia (Semantic Dementia) 01/2023 - 05/2011
6	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 03/2024 - 03/2016
5	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 04/2024 - 01/2013
4	Corticobasal Degeneration 04/2024 - 01/2016
4	Tauopathies 01/2024 - 01/2013
4	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018 - 01/2013
3	Disease Progression 03/2024 - 01/2013
3	Parkinson Disease (Parkinson's Disease) 01/2023 - 01/2013
2	Parkinsonian Disorders (Parkinsonism) 01/2023 - 01/2016
2	Dementia (Dementias) 01/2021 - 12/2016
1	Atrophy 04/2024
1	Proteostasis Deficiencies 01/2024
1	Protein Deficiency 01/2023
1	Neurobehavioral Manifestations 02/2016
1	Insulin Resistance 02/2015
1	Type 2 Diabetes Mellitus (MODY) 02/2015
1	Cognitive Dysfunction 11/2007

Drug/Important Bio-Agent (IBA)

16	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2013
11	Proteins (Proteins, Gene)FDA Link 03/2024 - 11/2007
4	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2013
3	ProgranulinsIBA 01/2023 - 03/2016
2	Cerebrospinal Fluid ProteinsIBA 03/2024 - 01/2021
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2020 - 01/2016
2	LipidsIBA 09/2019 - 01/2019
2	Oxytocin (Pitocin)FDA LinkGeneric 01/2018 - 01/2015
1	ProteomeIBA 03/2024
1	Dopa DecarboxylaseIBA 01/2023
1	EnzymesIBA 01/2023
1	MidkineIBA 01/2023
1	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2022
1	Carrier Proteins (Binding Protein)IBA 01/2019
1	6-fluoro-6-desoxyoxymorphone (FOXY)IBA 01/2018
1	MicroRNAs (MicroRNA)IBA 01/2018
1	Synaptotagmins (Synaptotagmin)IBA 12/2016
1	SynaptophysinIBA 12/2016
1	NeurograninIBA 12/2016
1	Lysosomal-Associated Membrane Protein 2IBA 01/2016
1	Muramidase (Lysozyme)IBA 01/2016
1	Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)IBA 07/2015
1	lysosomal proteinsIBA 07/2015
1	Cathepsin DIBA 07/2015
1	Transcription Factors (Transcription Factor)IBA 07/2015
1	Low Density Lipoprotein Receptor-Related Protein-6IBA 07/2015
1	ElementsIBA 07/2015
1	Insulin ReceptorIBA 02/2015
1	Threonine (L-Threonine)FDA Link 02/2015
1	Glucose (Dextrose)FDA LinkGeneric 02/2015
1	Alanine (L-Alanine)FDA Link 02/2015
1	AD 20 (AD-20)IBA 02/2015
1	Serine (L-Serine)FDA Link 02/2015
1	Apolipoproteins E (ApoE)IBA 11/2014
1	2- (1- (6- ((2- fluoroethyl)(methyl)amino)- 2- naphthyl)ethylidene)malononitrileIBA 01/2013
1	Memantine (Namenda)FDA Link 05/2011
1	Antidepressive Agents (Antidepressants)IBA 05/2011
1	Antipsychotic Agents (Antipsychotics)IBA 05/2011
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 05/2011

Therapy/Procedure

5	Therapeutics 01/2024 - 11/2007